A phase II study evaluating the combination of BMS-986205, an IDO1 inhibitor with nivolumab (NCT03854032) in stage II–IV patients with HNSCC, is still ongoing. This evidence concerns the gene IDO1 and head and neck squamous cell carcinoma.